In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Evolus Inc (NASDAQ: EOLS), with a price target of $35. The company’s shares opened today at $17.19.
Chen wrote:
“Based on our diligence, dermatologists and plastic surgeons appreciate the value proposition of Evolus’s botulinum toxin as a nearly identical product to market leader Botox sold at a discount. Therefore, we think DWP-450 could pick up meaningful market share if it is approved. and other potential upcoming catalysts should drive EOLS shares higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $35 12-month price target.”
According to TipRanks.com, Chen is a 1-star analyst with an average return of 0.0% and a 38.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolus Inc with a $29.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.50 and a one-year low of $6.75. Currently, Evolus Inc has an average volume of 424.4K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.
